Real Endpoints Appoints Jeff Berkowitz, CEO and Director

Madison-based Real Endpoints (RE) announced that Jeff Berkowitz, a 20-year veteran of the pharmaceutical, drug distribution, pharmacy and payer industries, has joined the company as CEO and member of the board of directors.

Berkowitz is an executives whose career has spanned most key verticals in global healthcare with executive committee and other senior roles at United Health Group, Walgreens Boots Alliance (formerly Walgreens), Merck and Schering-Plough.

“The seismic shifts in public policy, pricing, reimbursement and market access create enormous strategic challenges for biotech, pharma, payers, distributors and other key healthcare stakeholders,” said Berkowitz.  “Roger Longman and Norman Selby founded Real Endpoints to deliver practical solutions for achieving better patient outcomes and higher healthcare system value.  RE today has established itself as a leader in this effort — with extraordinary expertise, a strong portfolio of proprietary tools, and solutions, and deep client relationships. I am excited to join the company at this important stage and work with the team to significantly accelerate its growth, scale, and impact on patient health,” he continued.

“RE has been built on the fundamental principle that you can’t solve access and cost problems without understanding the complex interrelationships of the healthcare ecosystem – and building trusted relationships with each stakeholder,” said Roger Longman. “Jeff’s leadership roles and deep knowledge of the healthcare landscape, his past successes, as well as his broad network among payers, PBMs, distributors and biopharma will allow RE to continue to create innovative solutions in an increasingly complex and changing healthcare system.”

Most recently, Berkowitz served as an EVP at UnitedHealth Group, CEO of its Optum International business and as a strategic leader of OptumRx, its PBM.  He joined United from the Walgreens Boots Alliance, where he had been EVP and president, Pharma, Specialty and Market Access, responsible for a team of 5800 people charged with pricing, reimbursement, network contracting, drug procurement and all specialty pharmacy activities.  Before moving to Walgreens, Berowitz had spent 12 years at Schering-Plough and then Merck, ultimately as SVP, Global Market Access, accountable for all access, pricing, payor marketing, health outcomes and health technology assessments worldwide.  He began his career as a lawyer at the international firm, Proskauer.

To access more business news, visit NJB News Now.

Related Articles: